Command Palette

Search for a command to run...

JAGSNPHARM

219.41-0.63%
Market Cap
₹0.00 Cr
Stock P/E
0.00
ROCE
0.00%
ROE
0.00%
Book Value
₹0.00

You might have missed

No Recent News

No recent news available for this stock.

Shareholding

Holdings
Distribution
Promoter
Public
Others

From Last Concall

POSITIVES
  • Revenue growth and margin expansion driven by brand equity and marketing push.
  • Profitability improved sharply with PAT doubling and strong net margins.
NEGATIVES
  • Governance concern from CFO termination during probation.
  • Q1 margin expansion delayed due to higher marketing spend and related costs.

Peers Summary

Sector Leader

Jagsonpal Pharmaceuticals Ltd. shows significantly weaker financials compared to its peers, with no growth metrics and no profitability indicators. In contrast, companies like Cipla and Dr. Reddy's Laboratories demonstrate strong profitability and growth, positioning them as sector leaders. Jagsonpal may be viewed as a potential value pick due to low valuation metrics, but its lack of performance raises concerns.

Key Points
  • Jagsonpal Pharmaceuticals has zero growth in revenue, EPS, and profitability metrics, marking it as an underperformer in the sector.
  • Cipla Ltd. and Dr. Reddy's Laboratories stand out as leaders in profitability with strong ROE and EPS growth.
  • Value picks can be identified among companies with low PE and PBV ratios while maintaining good profitability.
Top Performers
Cipla Ltd.

Strong revenue growth, low PE ratio, and high profitability metrics.

Dr. Reddy's Laboratories Ltd.

Excellent EPS growth, low valuation ratios, and high ROE.

Mankind Pharma Ltd.

High growth rate in revenue and EPS with reasonable valuation.

Leveling the playing field in markets.

© 2025 EQHQ Technologies Pvt Ltd

"Information provided is for educational purposes only and not financial advice.